137 related articles for article (PubMed ID: 27347781)
1. Biodistribution and toxicity of orally administered poly (lactic-co-glycolic) acid nanoparticles to F344 rats for 21 days.
Navarro SM; Morgan TW; Astete CE; Stout RW; Coulon D; Mottram P; Sabliov CM
Nanomedicine (Lond); 2016 Jul; 11(13):1653-69. PubMed ID: 27347781
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of PLGA and PLGA/chitosan nanoparticles after repeat-dose oral delivery in F344 rats for 7 days.
Navarro SM; Darensbourg C; Cross L; Stout R; Coulon D; Astete CE; Morgan T; Sabliov CM
Ther Deliv; 2014 Nov; 5(11):1191-201. PubMed ID: 25491670
[TBL] [Abstract][Full Text] [Related]
3. The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats.
Simon LC; Sabliov CM
Drug Metab Rev; 2014 May; 46(2):128-41. PubMed ID: 24303927
[TBL] [Abstract][Full Text] [Related]
4. Transient aggregation of chitosan-modified poly(d,l-lactic-co-glycolic) acid nanoparticles in the blood stream and improved lung targeting efficiency.
Lee SY; Jung E; Park JH; Park JW; Shim CK; Kim DD; Yoon IS; Cho HJ
J Colloid Interface Sci; 2016 Oct; 480():102-108. PubMed ID: 27421112
[TBL] [Abstract][Full Text] [Related]
5. Compared in vivo toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles.
Aragao-Santiago L; Hillaireau H; Grabowski N; Mura S; Nascimento TL; Dufort S; Coll JL; Tsapis N; Fattal E
Nanotoxicology; 2016; 10(3):292-302. PubMed ID: 26573338
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
Guo M; Rong WT; Hou J; Wang DF; Lu Y; Wang Y; Yu SQ; Xu Q
Nanotechnology; 2013 Jun; 24(24):245101. PubMed ID: 23702815
[TBL] [Abstract][Full Text] [Related]
7. Chitosan-Coated Poly(lactic-co-glycolic acid)-Diiodinated boron-Dipyrromethene Nanoparticles Improve Tumor Selectivity and Stealth Properties in Photodynamic Cancer Therapy.
Voon SH; Tiew SX; Kue CS; Lee HB; Kiew LV; Misran M; Kamkaew A; Burgess K; Chung LY
J Biomed Nanotechnol; 2016 Jul; 12(7):1431-52. PubMed ID: 29336539
[TBL] [Abstract][Full Text] [Related]
8. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
Yang Y; Xie XY; Mei XG
Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
[TBL] [Abstract][Full Text] [Related]
9. Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles.
Lee C; Seo J; Hwang HS; Thao LQ; Lee S; Lee ES; Lee EH; Choi HG; Youn YS
Biomed Pharmacother; 2016 Mar; 78():226-233. PubMed ID: 26898446
[TBL] [Abstract][Full Text] [Related]
10. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles.
Shi L; Wang X; Zhao F; Luan H; Tu Q; Huang Z; Wang H; Wang H
Int J Nanomedicine; 2013; 8():2669-76. PubMed ID: 23926429
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
13. Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release.
Chhabra R; Grabrucker AM; Veratti P; Belletti D; Boeckers TM; Vandelli MA; Forni F; Tosi G; Ruozi B
Int J Pharm; 2014 Aug; 471(1-2):349-57. PubMed ID: 24882034
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles.
Durán-Lobato M; Muñoz-Rubio I; Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Martín-Banderas L
J Biomed Nanotechnol; 2014 Jun; 10(6):1068-79. PubMed ID: 24749401
[TBL] [Abstract][Full Text] [Related]
15. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
Mistry NP; Desai JL; Thakkar HP
J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
[TBL] [Abstract][Full Text] [Related]
16. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine strategy for optimizing delivery to outer hair cells by surface-modified poly(lactic/glycolic acid) nanoparticles with hydrophilic molecules.
Wen X; Ding S; Cai H; Wang J; Wen L; Yang F; Chen G
Int J Nanomedicine; 2016; 11():5959-5969. PubMed ID: 27877041
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.
Li M; Panagi Z; Avgoustakis K; Reineke J
Int J Nanomedicine; 2012; 7():1345-56. PubMed ID: 22419876
[TBL] [Abstract][Full Text] [Related]
19. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells.
Grabowski N; Hillaireau H; Vergnaud J; Santiago LA; Kerdine-Romer S; Pallardy M; Tsapis N; Fattal E
Int J Pharm; 2013 Oct; 454(2):686-94. PubMed ID: 23747506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
